Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
552-01-018 / 552-01-018 ISMRM Abstract

Principal component analysis (PCA) applied to ³¹P MR spectra from independent exams reveals reproducible metabolic signatures

Primary: Analysis Methods - Data Processing
Secondary: Analysis Methods - Classification and Prediction
552-01-018 · Novel Approaches to Spectroscopy · Wednesday, 13 May, 8:20 AM–9:56 AM · Power Pitch Theatre 2
552-01-018 · Novel Approaches to Spectroscopy · Wednesday, 13 May, 8:20 AM–9:56 AM · Power Pitch Theatre 2
Keywords: Cancer Metabolomics Magnetic Resonance Spectroscopy (MRS) Principal component analysis Predictive biomarkers
Accepted
Fernando Arias-Mendoza 1,2, Pradeep Kumar Gupta2, David Nelson2, David Tischfield2, Kavindra Nath2, Mariusz A Wasik3, Ravi Srinivasan1
1Advanced Imaging Research, Inc., Cleveland, United States of America
2University of Pennsylvania, Philadelphia, United States of America
3Department of Pathology, Fox Chase Cancer Center, Philadelphia, United States of America
Presenting Author: Fernando Arias-Mendoza

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Arias-Mendoza F. In vivo magnetic resonance spectroscopy in the evaluation of mitochondrial disorders. Mitochondrion. 2004;4(5-6):491-501. Epub 20040930. doi: 10.1016/j.mito.2004.07.034. PubMed PMID: 16120408. [doi] [pmid]
2. Arias-Mendoza F, Brown TR. In vivo measurement of phosphorous markers of disease. Dis Markers. 2003-2004;19(2-3):49-68. PubMed PMID: 15096705. [pmid]
3. Arias-Mendoza F, Nath K, Xu HN, Gupta PK, Li LZ. Assessment of Nicotinamide Adenine Dinucleotide in Human Tissues by In Vivo Phosphorus-31 Magnetic Resonance Spectroscopic Imaging at 1.5 Tesla. Adv Exp Med Biol. 2022;1395:323-8. doi: 10.1007/978-3-031-14190-4_52. PubMed PMID: 36527656. [doi] [pmid]
4. Arias-Mendoza F, Payne GS, Zakian KL, Schwarz AJ, Stubbs M, Stoyanova R, Ballon D, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR. In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed. 2006;19(4):504-12. doi: 10.1002/nbm.1057. PubMed PMID: 16763965. [doi] [pmid]
5. Abdoli A, Stoyanova R, Maudsley AA. Denoising of MR spectroscopic imaging data using statistical selection of principal components. MAGMA. 2016;29(6):811-22. Epub 20160603. doi: 10.1007/s10334-016-0566-z. PubMed PMID: 27260664; PMCID: PMC5699222. [doi] [pmid]
6. Brown TR, Stoyanova R. NMR spectral quantitation by principal-component analysis. II. Determination of frequency and phase shifts. J Magn Reson B. 1996;112(1):32-43. doi: 10.1006/jmrb.1996.0106. PubMed PMID: 8661304. [doi] [pmid]
7. Kuesel AC, Stoyanova R, Aiken NR, Li CW, Szwergold BS, Shaller C, Brown TR. Quantitation of resonances in biological 31P NMR spectra via principal component analysis: potential and limitations. NMR Biomed. 1996;9(3):93-104. PubMed PMID: 8892395. [pmid]
8. Stoyanova R, Brown TR. NMR spectral quantitation by principal component analysis. NMR Biomed. 2001;14(4):271-7. doi: 10.1002/nbm.700. PubMed PMID: 11410945. [doi] [pmid]
9. Stoyanova R, Brown TR. NMR spectral quantitation by principal component analysis. III. A generalized procedure for determination of lineshape variations. J Magn Reson. 2002;154(2):163-75. doi: 10.1006/jmre.2001.2486. PubMed PMID: 11846573. [doi] [pmid]
10. Stoyanova R, Nicholls AW, Nicholson JK, Lindon JC, Brown TR. Automatic alignment of individual peaks in large high-resolution spectral data sets. J Magn Reson. 2004;170(2):329-35. doi: 10.1016/j.jmr.2004.07.009. PubMed PMID: 15388097. [doi] [pmid]
11. Gupta PK, Li LZ, Singh DK, Nova S, Arias-Mendoza F, Orlovskiy S, Chawla S, Nelson DS, Farwell MD, Nath K. MRS and Optical Imaging Studies of Therapeutic Response to Combination Therapy Targeting BRAF/MEK in Murine Melanomas. Acad Radiol. 2025. Epub 2025/02/22. doi: 10.1016/j.acra.2025.01.035. PubMed PMID: 39984334. [doi] [pmid]
12. Gupta PK, Orlovskiy S, Arias-Mendoza F, Nelson DS, Nath K. (1)H and (31)P Magnetic Resonance Spectroscopic Metabolomic Imaging: Assessing Mitogen-Activated Protein Kinase Inhibition in Melanoma. Cells. 2024;13(14). Epub 20240719. doi: 10.3390/cells13141220. PubMed PMID: 39056801; PMCID: PMC11274771. [doi] [pmid]
13. Gupta PK, Orlovskiy S, Arias-Mendoza F, Nelson DS, Osborne A, Pickup S, Glickson JD, Nath K. Metabolic Imaging Biomarkers of Response to Signaling Inhibition Therapy in Melanoma. Cancers (Basel). 2024;16(2). Epub 20240115. doi: 10.3390/cancers16020365. PubMed PMID: 38254853; PMCID: PMC10814512. [doi] [pmid]
14. Arias-Mendoza F, Payne GS, Zakian K, Stubbs M, O'Connor OA, Mojahed H, Smith MR, Schwarz AJ, Shukla-Dave A, Howe F, Poptani H, Lee SC, Pettengel R, Schuster SJ, Cunningham D, Heerschap A, Glickson JD, Griffiths JR, Koutcher JA, Leach MO, Brown TR. Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma. Acad Radiol. 2013;20(9):1122-9. doi: 10.1016/j.acra.2013.04.013. PubMed PMID: 23931426; PMCID: PMC3810177. [doi] [pmid]
15. Arias-Mendoza F, Smith MR, Brown TR. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad Radiol. 2004;11(4):368-76. doi: 10.1016/s1076-6332(03)00721-9. PubMed PMID: 15109009; PMCID: 15109009. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/552-01-018